BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...company Seragon Pharmaceuticals Inc., a spinout of Aragon Pharmaceuticals Inc....
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...become chair. Heyman is chairman of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) and helped found cancer company Aragon Pharmaceuticals Inc....
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...see “ORIC Raises $55M” ). Founded by Charles Sawyers and Richard Heyman, the duo behind Aragon Pharmaceuticals...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...led to three acquisitions with upfront payments of at least $200 million: prostate cancer company Aragon Pharmaceuticals Inc....
BioCentury | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

...Calif.), which has now raised more than $175 million, was founded by the duo behind Aragon Pharmaceuticals...
...Kettering Cancer Center, and Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc....
...company’s near-term plans. Targets: CD73 (NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor Elizabeth S. Eaton, Staff Writer ORIC-101 Aragon Pharmaceuticals Inc. Ignyta...
BioCentury | May 9, 2016
Finance

ven and now

...thought the companies were worth even more and thus bid more." First to go was Aragon Pharmaceuticals Inc....
...High-affinity variants of signal regulatory protein alpha (SIRPA) to treat cancer 5/1/15 Series A $36.0 Aragon Pharmaceuticals Inc....
BioCentury | May 2, 2016
Finance

Pillars of strength

...returns but backers of its prior funds have been rewarded, Svennilson said. Prostate cancer company Aragon Pharmaceuticals Inc....
BioCentury | Apr 27, 2016
Top Story

The Column Group closes third fund

...$322 million in 2014. Each of two exits from the first fund, prostate cancer company Aragon Pharmaceuticals Inc....
BioCentury | Dec 7, 2015
Finance

Hard to resist

...The team and investors behind drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc. are back for...
BioCentury | Dec 3, 2015
Financial News

Oric raises $53 million series B

...preclinical development for castration-resistant prostate cancer (CRPC). Many of Oric's investors previously put money into Aragon Pharmaceuticals Inc....
Items per page:
1 - 10 of 58
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...company Seragon Pharmaceuticals Inc., a spinout of Aragon Pharmaceuticals Inc....
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...become chair. Heyman is chairman of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) and helped found cancer company Aragon Pharmaceuticals Inc....
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...see “ORIC Raises $55M” ). Founded by Charles Sawyers and Richard Heyman, the duo behind Aragon Pharmaceuticals...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...led to three acquisitions with upfront payments of at least $200 million: prostate cancer company Aragon Pharmaceuticals Inc....
BioCentury | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

...Calif.), which has now raised more than $175 million, was founded by the duo behind Aragon Pharmaceuticals...
...Kettering Cancer Center, and Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc....
...company’s near-term plans. Targets: CD73 (NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor Elizabeth S. Eaton, Staff Writer ORIC-101 Aragon Pharmaceuticals Inc. Ignyta...
BioCentury | May 9, 2016
Finance

ven and now

...thought the companies were worth even more and thus bid more." First to go was Aragon Pharmaceuticals Inc....
...High-affinity variants of signal regulatory protein alpha (SIRPA) to treat cancer 5/1/15 Series A $36.0 Aragon Pharmaceuticals Inc....
BioCentury | May 2, 2016
Finance

Pillars of strength

...returns but backers of its prior funds have been rewarded, Svennilson said. Prostate cancer company Aragon Pharmaceuticals Inc....
BioCentury | Apr 27, 2016
Top Story

The Column Group closes third fund

...$322 million in 2014. Each of two exits from the first fund, prostate cancer company Aragon Pharmaceuticals Inc....
BioCentury | Dec 7, 2015
Finance

Hard to resist

...The team and investors behind drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc. are back for...
BioCentury | Dec 3, 2015
Financial News

Oric raises $53 million series B

...preclinical development for castration-resistant prostate cancer (CRPC). Many of Oric's investors previously put money into Aragon Pharmaceuticals Inc....
Items per page:
1 - 10 of 58